On March 3, 2026, Richard Kender resigned from Longeveron Inc.'s Board of Directors and Audit Committee due to his new position at Seres Therapeutics; the company has appointed Dr. Roger Hajjar to the Audit Committee as a temporary measure. This event causes a temporary non-compliance with Nasdaq's listing rules, but is not due to any disagreement regarding company operations.